Management ChangeApr 24, 2026, 04:32 PM
NewAmsterdam Pharma CAO Louise Kooij to Depart
AI Summary
NewAmsterdam Pharma Company N.V. announced that Chief Accounting Officer Louise Kooij will depart the company effective August 31, 2026. A separation agreement was executed on April 24, 2026, outlining her severance package. This includes a lump sum payment equal to twelve months of her base salary and a pro-rated 2026 annual cash bonus. Additionally, the company agreed to extend the vesting of her outstanding stock options and restricted stock unit awards through January 10, 2027, with the exercise period for vested options expiring on February 10, 2027.
Key Highlights
- Chief Accounting Officer Louise Kooij's employment ends August 31, 2026.
- Separation agreement includes 12 months of base salary as lump sum.
- Kooij to receive a pro-rated 2026 annual cash bonus.
- Vesting of outstanding stock options and RSUs extended to January 10, 2027.
- Exercise period for vested stock options expires February 10, 2027.
Price Impact
More from NAMS